SWOG S1820: A pilot randomized trial of the Altering Intake, Managing Bowel Symptoms Intervention in Survivors of Rectal Cancer.

Autor: Sun V; Department of Population Sciences, City of Hope, Duarte, California, USA.; Department of Surgery, City of Hope, Duarte, California, USA., Guthrie KA; SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Crane TE; Division of Medical Oncology, Miller School of Medicine, University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, USA., Arnold KB; SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Colby S; SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Freylersythe SG; Division of Medical Oncology, Miller School of Medicine, University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, USA., Braun-Inglis C; University of Hawaii Cancer Center, Honolulu, Hawaii, USA., Topacio R; Cancer Research and Biostatistics, Seattle, Washington, USA., Messick CA; The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Carmichael JC; University of California Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, USA., Muskovitz AA; William Beaumont Hospital, Sterling Heights, Michigan, USA., Nashawaty M; Minnesota Oncology (Metro Minnesota Community Oncology Research Consortium), Edina, Minnesota, USA., Bajaj M; Illinois Cancer Care (Heartland Cancer Research NCORP), Peoria, Illinois, USA., Cohen SA; Fred Hutchinson Cancer Center, Seattle, Washington, USA., Flaherty DC; Valley Health Surgical Oncology (Virginia Commonwealth University Massey Cancer Center Minority Underserved NCORP), Winchester, Virginia, USA., O'Rourke MA; Prisma Health Cancer Institute (NCORP of the Carolinas Prisma Health NCORP), Greenville, South Carolina, USA., Jones L; Research Advocate., Krouse RS; Perelman School of Medicine, University of Pennsylvania and the Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA., Thomson CA; University of Arizona Cancer Center, Tucson, Arizona, USA.; Department of Health Promotion Sciences, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, Arizona, USA.
Jazyk: angličtina
Zdroj: Cancer [Cancer] 2024 Jul 01; Vol. 130 (13), pp. 2384-2394. Date of Electronic Publication: 2024 Feb 22.
DOI: 10.1002/cncr.35264
Abstrakt: Background: Survivors of rectal cancer experience persistent bowel dysfunction after treatments. Dietary interventions may be an effective approach for symptom management and posttreatment diet quality. SWOG S1820 was a pilot randomized trial of the Altering Intake, Managing Symptoms in Rectal Cancer (AIMS-RC) intervention for bowel dysfunction in survivors of rectal cancer.
Methods: Ninety-three posttreatment survivors were randomized to the AIMS-RC group (N = 47) or the Healthy Living Education attention control group (N = 46) after informed consent and completion of a prerandomization run-in. Outcome measures were completed at baseline and at 18 and 26 weeks postrandomization. The primary end point was total bowel function score, and exploratory end points included low anterior resection syndrome (LARS) score, quality of life, dietary quality, motivation, self-efficacy, and positive/negative affect.
Results: Most participants were White and college educated, with a mean age of 55.2 years and median time since surgery of 13.1 months. There were no statistically significant differences in total bowel function score by group, with the AIMS-RC group demonstrating statistically significant improvements in the exploratory end points of LARS (p = .01) and the frequency subscale of the bowel function index (p = .03). The AIMS-RC group reported significantly higher acceptability of the study.
Conclusions: SWOG S1820 did not provide evidence of benefit from the AIMS-RC intervention relative to the attention control. Select secondary end points did demonstrate improvements. The study was highly feasible and acceptable for participants in the National Cancer Institute Community Oncology Research Program. Findings provide strong support for further refinement and effectiveness testing of the AIMS-RC intervention.
(© 2024 American Cancer Society.)
Databáze: MEDLINE
Externí odkaz: